Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CAR-Expressing Natural Killer Cells for Cancer Retargeting.
Kloess S, Kretschmer A, Stahl L, Fricke S, Koehl U. Kloess S, et al. Among authors: koehl u. Transfus Med Hemother. 2019 Feb;46(1):4-13. doi: 10.1159/000495771. Epub 2019 Feb 5. Transfus Med Hemother. 2019. PMID: 31244577 Free PMC article. Review.
Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients.
Munkelt D, Koehl U, Kloess S, Zimmermann SY, Kalaäoui RE, Wehner S, Schwabe D, Lehrnbecher T, Schubert R, Kreuter J, Klingebiel T, Esser R. Munkelt D, et al. Among authors: koehl u. Cancer Chemother Pharmacol. 2008 Oct;62(5):821-30. doi: 10.1007/s00280-007-0669-3. Epub 2008 Feb 2. Cancer Chemother Pharmacol. 2008. PMID: 18246351
IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.
Huenecke S, Zimmermann SY, Kloess S, Esser R, Brinkmann A, Tramsen L, Koenig M, Erben S, Seidl C, Tonn T, Eggert A, Schramm A, Bader P, Klingebiel T, Lehrnbecher T, Passweg JR, Soerensen J, Schwabe D, Koehl U. Huenecke S, et al. Among authors: koehl u. J Immunother. 2010 Feb-Mar;33(2):200-10. doi: 10.1097/CJI.0b013e3181bb46f7. J Immunother. 2010. PMID: 20145545 Clinical Trial.
IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.
Kloess S, Huenecke S, Piechulek D, Esser R, Koch J, Brehm C, Soerensen J, Gardlowski T, Brinkmann A, Bader P, Passweg J, Klingebiel T, Schwabe D, Koehl U. Kloess S, et al. Among authors: koehl u. Eur J Immunol. 2010 Nov;40(11):3255-67. doi: 10.1002/eji.201040568. Epub 2010 Oct 27. Eur J Immunol. 2010. PMID: 21061445 Free article.
NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.
Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schönfeld K, Tonn T, Huebener N, Lode HN, Koehl U, Wels WS. Esser R, et al. Among authors: koehl u. J Cell Mol Med. 2012 Mar;16(3):569-81. doi: 10.1111/j.1582-4934.2011.01343.x. J Cell Mol Med. 2012. PMID: 21595822 Free PMC article.
IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study.
Brehm C, Huenecke S, Quaiser A, Esser R, Bremm M, Kloess S, Soerensen J, Kreyenberg H, Seidl C, Becker PS, Mühl H, Klingebiel T, Bader P, Passweg JR, Schwabe D, Koehl U. Brehm C, et al. Among authors: koehl u. PLoS One. 2011;6(11):e27351. doi: 10.1371/journal.pone.0027351. Epub 2011 Nov 9. PLoS One. 2011. PMID: 22096557 Free PMC article. Clinical Trial.
Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol.
Koehl U, Brehm C, Huenecke S, Zimmermann SY, Kloess S, Bremm M, Ullrich E, Soerensen J, Quaiser A, Erben S, Wunram C, Gardlowski T, Auth E, Tonn T, Seidl C, Meyer-Monard S, Stern M, Passweg J, Klingebiel T, Bader P, Schwabe D, Esser R. Koehl U, et al. Front Oncol. 2013 May 17;3:118. doi: 10.3389/fonc.2013.00118. eCollection 2013. Front Oncol. 2013. PMID: 23730623 Free PMC article.
Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy.
Brehm C, Huenecke S, Esser R, Kloess S, Quaiser A, Betz S, Zimmermann O, Soerensen J, Passweg JR, Klingebiel T, Schwabe D, Bader P, Koehl U. Brehm C, et al. Among authors: koehl u. Cancer Immunol Immunother. 2014 Aug;63(8):821-33. doi: 10.1007/s00262-014-1556-5. Epub 2014 May 8. Cancer Immunol Immunother. 2014. PMID: 24806448 Free PMC article. Clinical Trial.
152 results